Details of the Drug

General Information of Drug (ID: DMBIZ7H)

Drug Name
ICT-107
Indication
Disease Entry ICD 11 Status REF
Brain cancer 2A00 Phase 3 [1]
Recurrent glioblastoma 2A00.00 Phase 3 [2]
Glioblastoma multiforme 2A00.0 Phase 2 [3]
Drug Type
Vaccine
Cross-matching ID
TTD ID
D0M1RD

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 13 receptor alpha-2 (IL13RA2) TTMPZ7V I13R2_HUMAN Not Available [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Brain cancer
ICD Disease Classification 2A00
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin 13 receptor alpha-2 (IL13RA2) DTT IL13RA2 4.40E-01 2.46 1
Interleukin 13 receptor alpha-2 (IL13RA2) DTT IL13RA2 5.77E-05 4.14 2.11
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT01280552) A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM). U.S. National Institutes of Health.
4 Clinical pipeline report, company report or official report of ImmunoCellular Therapeutics.